Applied Genetic Technologies (AGTC) Reports Q2 Loss of $0.29/Share

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. HUBS
2. EXPE
3. ARM
4. FIS
5. BROS
6. QCOM
7. DDOG
8. EW
9. ZG
10. CPAY

Go back to Applied Genetic Technologies (AGTC) Reports Q2 Loss of $0.29/Share

AGTC Announces Financial Results and Business Update for the Quarter Ended December 31, 2017

February 9, 2018 7:00 AM EST

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Feb. 09, 2018 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced financial results for the quarter ended December 31, 2017.

Our primary focus for 2018 is enrolling patients in the companys ongoing Phase 1/2 clinical trials for our XLRS, ACHM and XLRP product candidates, said Sue Washer, President and CEO of AGTC. We have taken steps to add clinical staff, employ additional resources and increase awareness of our trials through patient... More